Drug intelligence / Profile preview

fluoxetine + prednisolone + ivermectin

Development stage
Unknown
Lead developer
Eli Lilly
Modality
Small Molecules
Administration
Oral
01

Overview

Fluo-Pred-Iver is a combined regimen of three medications: fluoxetine, prednisolone, and ivermectin. This combination has been investigated as a potential treatment for COVID-19, particularly in ambulatory patients with mild disease. The rationale behind this combination appears to be: 1. **Fluoxetine**: A selective serotonin reuptake inhibitor (SSRI) that may inhibit serotonin production in the body and decrease serotonin levels in platelets, potentially reducing excessive serotonin production during inflammatory storms and lung damage in COVID-19. 2. **Prednisolone**: A corticosteroid with anti-inflammatory properties. 3. **Ivermectin**: An antiparasitic agent that has shown some in vitro antiviral activity. It may work by inhibiting the importin (IMP) α/β receptor, which is responsible for transmitting viral proteins into the host cell nucleus. The combination has been studied in clinical trials to evaluate its efficacy in preventing disease progression in patients with mild COVID-19.

Other names
fluoxetine-Oriol Mitja-COVID-19
02

Targets

GR (Glucocorticoid receptor)SERT (Sodium-dependent serotonin transporter)KPNA1 (Importin subunit alpha-5)

Beyond the preview

Go deeper on fluoxetine + prednisolone + ivermectin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on fluoxetine + prednisolone + ivermectin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call